Last reviewed · How we verify
L-T4
At a glance
| Generic name | L-T4 |
|---|---|
| Sponsor | Zhongshan Hospital Xiamen University |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2,PHASE3)
- Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism
- Neuroendocrine Response in Pediatric Febrile Seizures
- T4/T3 Therapy in Hypothyroidism (PHASE2)
- Dosing of LT4 in Older Individuals (PHASE4)
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans (PHASE2)
- SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial (NA)
- A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-T4 CI brief — competitive landscape report
- L-T4 updates RSS · CI watch RSS
- Zhongshan Hospital Xiamen University portfolio CI